Mankind Pharma reported improved operational performance for the fourth quarter of FY26, driven by steady growth in its domestic formulations business and rising contribution from chronic therapies.
The company recorded double-digit revenue growth alongside a notable improvement in operating margins. While domestic demand remained supportive, growth in the international business segment continued to face pressure due to geopolitical challenges in certain markets.
Mankind Pharma reported revenue of ₹3,443 crore for the March quarter, reflecting an increase of 11.8% compared to ₹3,079.4 crore in the corresponding period last year.
EBITDA for the quarter rose 36.1% year-on-year to ₹930 crore from ₹683 crore. EBITDA margin expanded to 27% from 22.2% in the previous year’s quarter, indicating improved operational efficiency and product mix.
Net profit for the quarter stood at ₹420.8 crore, remaining broadly stable compared to ₹425.1 crore reported a year earlier.
According to Vice Chairman and Managing Director Rajeev Juneja, the company delivered around 12% revenue growth during the quarter, supported largely by its India business.
The domestic business, excluding the Consumer Healthcare segment, grew approximately 13% year-on-year. The company stated that chronic therapies continued to contribute significantly to growth during the period.
Mankind Pharma reported strong growth in key chronic therapy segments. The cardiac portfolio recorded growth of 14.7%, while the anti-diabetes segment expanded by 11.6% during the quarter.
The company said chronic therapies now contribute nearly 40% of domestic sales, reflecting a gradual shift towards specialised and recurring treatment categories within its portfolio.
While domestic operations remained resilient, the company indicated that growth in international markets remained relatively muted. Geopolitical conditions in certain overseas regions continued to impact business momentum and overall expansion in the international segment.
Shares of Mankind Pharma closed 1% lower at ₹2,470 ahead of the earnings announcement. However, on May 20, 2026, at 11:08 AM, the stock was trading at ₹2,569.80 on the NSE, up ₹77.20 or 3.10% from the previous close of ₹2,492.60.
Read More: Jindal India Completes ₹1,500 Crore Expansion Project in West Bengal with New Coating Facility.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Mankind Pharma’s fourth-quarter performance reflected steady domestic demand, higher contribution from chronic therapies and improved operating margins. While international business growth remained subdued, the company’s India-focused operations continued to support overall revenue and profitability during the quarter.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: May 20, 2026, 11:16 AM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
